Molnupiravir for COVID-19 treatment

Table of contents

Remark: Getting Molnupiravir as COVID-19 Medication at H.U.M. Clinic costs 3,300 THB including Molnupiravir Medication and Doctor Consultation Fee. The other symptomatic treatment starts at 300 THB

What is Molnupiravir for COVID-19 treatment ?

Overview of Molnupiravir

Molnupiravir is an oral antiviral medication derived from beta-D-N4-hydroxycytidine (NHC). It converts in the body to an active form, effectively targeting the virus.

How Does Molnupiravir Work?

Molnupiravir reduces the SARS-CoV-2 virus’s ability to replicate, lowering the viral load and helping reduce symptoms and spread, especially in high-risk individuals.

FDA Approve Molnupiravir for COVID-19 Treatment

On December 23, 2021, the FDA issued an Emergency Use Authorization (EUA) for Molnupiravir for adults with mild to moderate COVID-19 within 5 days of symptom onset and at high risk of severe disease. This provides a crucial treatment option in combating COVID-19.1
molnupiravir needed patient

How effective of Molnupiravir for COVID-19 treatment

Recent updates from the MOVe-OUT study2 highlight Molnupiravir’s effectiveness in treating COVID-19. The study showed a 30% relative risk reduction in hospitalization or death compared to a placebo, indicating significant protection against severe outcomes. Additionally, Molnupiravir demonstrated an 89% relative risk reduction in death, showcasing its potential to save lives, especially among high-risk patients.
In terms of safety, side effects were similar between the Molnupiravir and placebo groups, with 35.0% and 39.6% of patients reporting side effects, respectively. This suggests that Molnupiravir does not significantly increase the risk of adverse effects, making it a relatively safe option for mild to moderate COVID-19.
These findings underscore Molnupiravir’s role in reducing severe outcomes and mortality, positioning it as a valuable tool in the fight against COVID-19.

Where can I get Molnupiravir for COVID-19 treatment ?

In Thailand, Molnupiravir is a controlled drug regulated by the Thai FDA, meaning only hospitals and specialist medical clinics can prescribe it. To obtain this medication, consult a healthcare provider at an approved facility according to the Thai FDA guideline dispensing covid-19 medication3.
Pharmacies in Thailand are not authorized to sell or prescribe Molnupiravir. If you find it in a pharmacy, report it to the Thai FDA and do not purchase it, as it could be counterfeit or improperly stored, posing health risks.
For safety, always get Molnupiravir through legitimate medical channels. Ensure you receive a prescription from a qualified professional at an accredited hospital or clinic. This ensures you get a genuine product and the correct dosage for your needs.

How much is Molnupiravir in Thailand ?

In Thailand, multiple generic brands of Molnupiravir are available, including the original LAGEVRIO from Canada/USA and generics from Thailand and India. The price in private hospitals ranges from 50-100 THB per tablet.
Total treatment costs in hospitals include the price of tablets, hospital charges, doctor fees, and supportive medicines, typically ranging from 4,500 to 8,000 THB.
Treatment at a medical clinic is generally more affordable, with total costs usually starting from 2,500 to 3,500 THB. This makes clinics a more accessible option while ensuring professional care.
Understanding these cost differences helps patients make informed decisions about where to receive their Molnupiravir treatment based on their financial situation and medical needs. Choosing the right setting for treatment ensures effective care while managing costs.

Should I take Molnupiravir for COVID-19 ?

For individuals with mild to moderate COVID-19 symptoms who are at risk of developing severe illness, Molnupiravir should be taken within 5 days of symptom onset. This early intervention is crucial to maximize the drug’s effectiveness in preventing the progression of the disease.

Who Should Consider Taking Molnupiravir ?

Molnupiravir is particularly recommended for patients with the following risk factors4:
  • Age over 60 years: Older adults are at a higher risk of severe COVID-19 outcomes.
  • Underlying lung diseases: Conditions such as COPD and asthma increase the vulnerability to severe respiratory complications.
  • Chronic kidney disease: Compromised kidney function can exacerbate COVID-19 symptoms.
  • Heart disease: Patients with cardiovascular issues are more likely to experience severe COVID-19.
  • Stroke: A history of stroke can increase the risk of severe illness.
  • Active cancer: Cancer patients, particularly those undergoing treatment, have weakened immune systems.
  • Diabetes: High blood sugar levels can complicate the body’s response to infection.
  • Obesity: A BMI over 30 or a body weight over 90 kg.
  • Cirrhosis of the liver: Especially for patients with Child-Pugh class B or above, liver disease can complicate COVID-19.
  • Immunocompromised state: Conditions or treatments that weaken the immune system heighten the risk.
  • HIV infection: Particularly if CD4 cell count is below 200 cells/mm3, indicating a weakened immune response.

What To Monitor During Taking Molnupiravir

Patients should monitor their symptoms closely after starting Molnupiravir. If there is no improvement within 24-48 hours, hospitalization might be necessary. Immediate medical attention ensures that any escalation in symptoms can be managed promptly, reducing the risk of severe complications.
By taking Molnupiravir early and monitoring their condition, high-risk patients can significantly reduce the likelihood of severe outcomes, ensuring a better chance of recovery from COVID-19.

What is the dosage of Molnupiravir for COVID-19 treatment ?

Molnupiravir is available in 200 mg capsule. For treating COVID-19, the recommended dosage is 800 mg (four capsules) every 12 hours for 5 days.
If you have renal or liver impairment, please consult with a specialist doctor before starting the treatment.

What should I know before taking Molnupiravir ?

Molnupiravir should be started within 5 days after COVID-19 symptoms appear. It reduces hospitalization and death rates by 30% compared to a placebo and is approved for patients aged 18 and older.

Molnupiravir and Pregnancy

  • Pregnancy and Breastfeeding: Molnupiravir is unsafe for pregnant or breastfeeding women.
  • Women: Use effective birth control while taking Molnupiravir and for at least 4 days after the last dose.
  • Men: If your partner is pregnant or could become pregnant, use birth control during treatment and for 3 months after the last dose.
Due to potential mutagenic effects, Molnupiravir is not recommended for those not at high risk of severe COVID-19.

What are Possible Side Effects of Molnupiravir

  • Severe Allergic Reactions: Hives, difficulty breathing, and swelling of the face, lips, tongue, or throat.
  • Common Side Effects: Headaches, dizziness, diarrhea, and nausea.
Consult a healthcare provider before starting Molnupiravir to ensure it is the right treatment for you.

How to get COVID-19 treatment at H.U.M. Clinic

If you’ve tested positive for COVID-19, H.U.M. Clinic is here to help. Our licensed medical clinic offers comprehensive care with English-speaking doctors and staff for clear communication and understanding of your needs.
Contact us, H.U.M. Clinic, today for a consultation on COVID-19 treatment and experience our comprehensive healthcare services. Self appointment can also be made. Let us help you navigate this challenging time with confidence and care.

Why Choose H.U.M. Clinic?

  • Expert Care: Experienced medical professionals dedicated to top-quality care.
  • Convenient Telemedicine: Access consultations from the safety of your home.
  • Contactless Medicine Delivery: Secure medication delivery directly to your room to ensure safety and prevent infection.
References
  1. https://www.fda.gov/ ↩︎
  2. https://www.nejm.org/ ↩︎
  3. https://covid19.dms.go.th/ ↩︎
  4. https://www.nice.org.uk/ ↩︎

Related Content:

  Make Appointment
 Make Appointment